Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“Although daptomycin should not be used in patients with pneumonia because of inactivation by pulmonary surfactant [182], it can be used in septic pulmonary emboli [183].”
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
“, tigecycline and daptomycin), which are often associated with increased cost, diminished efficacy, and a greater risk of toxicity compared with the cost, efficacy, and risk of toxicity of first-line antibiotic therapies (Table 1) (49, 50).”
BackgroundMethicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
General Principles of Antimicrobial Therapy
Leekha, S., Terrell, C. L., & Edson, R. S. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0639 · Cited by 878
“Daptomycin, an excellent bactericidal agent against gram-positive bacteria, is not useful for treatment of pneumonia (eg, pneumococcal pneumonia) because it is inactivated by lung surfactant.(18) Many antibiotics (eg, aminoglycosides) are less active in the low-oxygen, low-pH, and high-protein environment of abscesses…”
BackgroundHurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
“For example, daptomycin is inactive against respiratory infections, and this is thought to be due to high levels of protein binding, as occurs in epithelial lining fluid (ELF) obtained by bronchoalveolar lavag”
Hover, B. M., Kim, S.-H., Katz, M., Charlop-Powers, Z., Owen, J. G., Ternei, M. A., Maniko, J., Estrela, A. B., Molina, H., Park, S., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0110-1 · Cited by 432
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
“The lack of efficacy of daptomycin in CAP is thought to be due to a reduction of daptomycin activity in the presence of lung surfactant.(139) Daptomycin maintains its bactericidal activity in the stationary phase of bacterial growth but the importance of this in clinical therapy requires further investigation.”
BackgroundSkin and Soft-Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus
Daum, R. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070747 · Cited by 417
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Baltz, R. H., Miao, V., & Wrigley, S. K. (2005) · Natural Product Reports · doi:10.1039/b416648p · Cited by 393
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
The action mechanism of daptomycin
Taylor, S. D., & Palmer, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.052 · Cited by 298
Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
Baltz, R. H. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.02.031 · Cited by 267
Kakoullis, L., Papachristodoulou, E., Chra, P., & Panos, G. (2021) · Antibiotics · doi:10.3390/antibiotics10040415 · Cited by 235
“in pulmonary infections, as PG makes up approximately 10% of lung surfactant, leading to daptomycin inserting directly into the surfactant layer, as it is unable to distinguish between the PG found in the comparatively small surface area of bacteria and that found in the vast layer of surfactant [17].”
BackgroundSerious Infections Caused by Methicillin‐Resistant Staphylococcus aureus
Boucher, H., Miller, L. G., & Razonable, R. R. (2010) · Clinical Infectious Diseases · doi:10.1086/653519 · Cited by 252
“Clinical trials examining the use of daptomycin for treatment of pneumonia failed to demonstrate efficacy equivalent to comparators, and daptomycin was subsequently found to interact with pulmonary surfactant, resulting in the inhibition of its antibacterial activity [54, 55].”
BackgroundCommunity‐Associated Methicillin‐Resistant Staphylococcus aureus
Weber, J. T. (2005) · Clinical Infectious Diseases · doi:10.1086/430788 · Cited by 244
A Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
“In contrast, ceftriaxone reduces the bacterial burden in this setting by greater than 5 orders of magnitude (50).”
BackgroundInfluentialComplications of seasonal and pandemic influenza
Rothberg, M. B., & Haessler, S. D. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181c92eeb · Cited by 236
“aureus pneumonia should be avoided because this drug is inhibited by pulmonary surfactant, leading to clinical failure (87).”
BackgroundGrein, F., Müller, A., Scherer, K. M., Liu, X., Ludwig, K. C., Klöckner, A., Strach, M., Sahl, H.-G., Kubitscheck, U., & Schneider, T. (2020) · Nature Communications · doi:10.1038/s41467-020-15257-1 · Cited by 230
Nathwani, D., Morgan, M., Masterton, R. G., Dryden, M., Cookson, B. D., French, G., & Lewis, D. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn096 · Cited by 217
Daptomycin, a Bacterial Lipopeptide Synthesized by a Nonribosomal Machinery
Robbel, L., & Marahiel, M. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.128181 · Cited by 206
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK
Brown, N. M., Goodman, A. L., Horner, C., Jenkins, A., & Brown, E. M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaa114 · Cited by 196
Treatment of Staphylococcus aureus Infections
David, M. Z., & Daum, R. S. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_42 · Cited by 185
“Daptomycin, which is inactivated by pulmonary surfactant, is not recommended (Silverman et al. 2005).”
BackgroundMarty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., & Pillai, S. K. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.595-597.2006 · Cited by 199
“In these cases, it may be postulated that the presence of nondebrided infected bone, subtherapeutic bone levels (8), or microenvironment interactions (13) may have contributed to the development of resistance.”
BackgroundPea, F., & Viale, P. (2009) · Critical Care · doi:10.1186/cc7774 · Cited by 194
“Moreover, it should be borne in mind that drugs with excellent in vitro activity against multiresistant pathogens may be inactivated at the infection site, as in the case of daptomycin, which is not applicable to lung infections because of its inactivation by pulmonary surfactant [15].”
BackgroundChallenges of antibacterial discovery revisited
Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., & Payne, D. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05828.x · Cited by 193
Hidron, A. I., Low, C. E., Honig, E. G., & Blumberg, H. M. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70133-1 · Cited by 180
Staphylococcus aureus (Including Staphylococcal Toxic Shock)
QUE, Y.-A., & MOREILLON, P. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00195-8 · Cited by 172
Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus
Boucher, H. W., & Sakoulas, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520655 · Cited by 174
“Clinical studies showed that daptomycin for the treatment of pneumonia failed, and it was shown that daptomycin is inactivated by surfactant [19].”
BackgroundThe Potential of Antimicrobial Peptides as Biocides
Laverty, G., Gorman, S. P., & Gilmore, B. F. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12106566 · Cited by 171
“Increased amphiphilicity and integration of daptomycin into bacterial membranes occurs via the acyl chains [109–113].”
BackgroundKhan, S., Tøndervik, A., Sletta, H., Klinkenberg, G., Emanuel, C., Onsøyen, E., Myrvold, R., Howe, R. A., Walsh, T. R., Hill, K. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00525-12 · Cited by 171
Multidrug-resistant bacteria in solid organ transplant recipients
Cervera, C., van Delden, C., Gavaldà, J., Welte, T., Akova, M., & Carratalà, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12687 · Cited by 167
“Daptomycin is inactivated by lung surfactant [91].”
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
Roberts, K. D., Zhu, Y., Azad, M. A. K., Han, M., Wang, J., Wang, L., Yu, H. H., Horne, A. S., Pinson, J., Rudd, D. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29234-3 · Cited by 164
Pertel, P. E., Bernardo, P., Fogarty, C., Matthews, P., Northland, R., Benvenuto, M., Thorne, G. M., Luperchio, S. A., Arbeit, R. D., & Alder, J. (2008) · Clinical Infectious Diseases · doi:10.1086/533441 · Cited by 162
“aureus pneumonia [4].”
BackgroundInfluentialSelf-citationGould, F. K., Brindle, R. J., Chadwick, P. R., Fraise, A. P., Hill, S., Nathwani, D., Ridgway, G. L., Spry, M. J., Warren, R. E., & on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp065 · Cited by 173
“Of the new agents, daptomycin is inactivated by lung surfactant and therefore not recommended in the management of respiratory tract infection.(124) Recommendation 12: The treatment of infections in patients with bronchiectasis or chronic suppurative lung disease without pneumonia, where MRSA is deemed significant, is…”
BackgroundMaschmeyer, G., Carratalà, J., Buchheidt, D., Hamprecht, A. G., Heußel, C. P., Kahl, C., Lorenz, J., Neumann, S., Rieger, C. T., Ruhnke, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu192 · Cited by 151
“Except from selected patients who also have a severe cellular immunosuppression, antiviral agents such as ganciclovir are not recommended for early pre-emptive therapy in febrile neutropenic patients with LI (E-II).”
BackgroundInfluentialThe bacterial envelope as a target for novel anti-MRSA antibiotics
Françoise Van Bambeke, A., Mingeot‐Leclercq, M., Struelens, M. J., & Tulkens, P. M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.004 · Cited by 149
Schramm, G. E., Johnson, J. A., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000227655.41566.3e · Cited by 145
“Less than ideal results have been observed in previous evaluations of presumed appropriate treatment of MRSA infections due to potential drug-related factors such as lack of adequate tissue penetration for specific antimicrobial agents (30, 32, 33).”
BackgroundProtein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria
Blaskovich, M. A. T., Hansford, K. A., Gong, Y., Butler, M. S., Muldoon, C. A., Huang, J. X., Ramu, S., Silva, A. B., Cheng, M., Kavanagh, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02123-w · Cited by 143
Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids
Pader, V., Hakim, S., Painter, K. L., Wigneshweraraj, S., Clarke, T. B., & Edwards, A. M. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.194 · Cited by 142
Daptomycin: A Review 4 Years after First Approval
Sauermann, R., Rothenburger, M., Graninger, W., & Joukhadar, C. (2007) · Pharmacology · doi:10.1159/000109868 · Cited by 141
“Of these, 56p had SSSI, 18p had bacteremia, 13p had osteomyelitis. Seventy-six percent had received other antibiotics prior to daptomycin. Daptomycin doses were 4 mg/kg in 51p and ≥6 mg/kg in 37p of patients. Overall, 92p of patients achieved clinical success, defined as improvement or cure. Highest success rates were…”
BackgroundAdvances in antimicrobial peptides: From mechanistic insights to chemical modifications
Yang, R., Ma, X., Peng, F., Wen, J., Allahou, L. W., Williams, G. R., Knowles, J. C., & Poma, A. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108570 · Cited by 145
“Moreover, Daptomycin cannot be used for pulmonary infections, as it is inactivated by lung surfactants, limiting its range of indications (Silverman et al., 2005).”
Baltz, R. H. (2012) · ACS Synthetic Biology · doi:10.1021/sb3000673 · Cited by 133
Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort
Ledger, E. V. K., Sabnis, A., & Edwards, A. M. (2022) · Microbiology · doi:10.1099/mic.0.001136 · Cited by 137
“It is inactive against Gramnegative bacteria and cannot be used to treat lung infections as it is inactivated by the phospholipids in lung surfactant [4].”
BackgroundKaplan, S. L. (2005) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2005.07.006 · Cited by 128
Sader, H. S., Streit, J. M., Fritsche, T. R., & Jones, R. N. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01550.x · Cited by 127
“However, daptomycin is not indicated for treatment of pneumonia, because of its inhibition by pulmonary surfactants [15].”
BackgroundRecent Advances in Biomedical, Therapeutic and Pharmaceutical Applications of Microbial Surfactants
Ceresa, C., Fracchia, L., Fedeli, E., Porta, C., & Banat, I. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040466 · Cited by 136
Future Challenges And Treatment Of Staphylococcus Aureus Bacteremia With Emphasis On MRSA
Rasmussen, R. V., Fowler, V. G., Skov, R. L., & Bruun, N. E. (2010) · Future Microbiology · doi:10.2217/fmb.10.155 · Cited by 144
“As it is inactivated by pulmonary surfactant, daptomycin should not be used in the setting of pneumonia [137].”
Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know
Vandecasteele, S. J., Boelaert, J. R., & Vriese, A. S. D. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01590309 · Cited by 141
“Daptomycin has failed to prove value in the treatment of MRSA pneumonia because of its inactivation by surfactant (121).”
BackgroundManagement of Methicillin‐ResistantStaphylococcus aureusBacteremia
Cosgrove, S. E., & Fowler, V. G. (2008) · Clinical Infectious Diseases · doi:10.1086/533595 · Cited by 133
“because it is inactivated by pulmonary surfactant [56].”
BackgroundDiagnosis and treatment of Panton–Valentine leukocidin (PVL)-associated staphylococcal pneumonia
Morgan, M. S. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.04.019 · Cited by 123
New antimicrobial agents for the treatment of Gram-positive bacterial infections
Aksoy, D. Y., & Ünal, S. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01933.x · Cited by 124
“The lack of efficacy of daptomycin in treating community-acquired pneumonia is thought to be a consequence of a reduction of daptomycin activity in the presence of lung surfactant [45].”
BackgroundMucin Binding Reduces Colistin Antimicrobial Activity
Huang, J. X., Blaskovich, M. A. T., Pelingon, R., Ramu, S., Kavanagh, A. M., Elliott, A. G., Butler, M. S., Montgomery, A. B., & Cooper, M. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00808-15 · Cited by 115
Current Treatment Options for Community‐Acquired Methicillin‐ResistantStaphylococcus aureusInfection
Moellering, R. C. (2008) · Clinical Infectious Diseases · doi:10.1086/529445 · Cited by 115
“Daptomycin is inactivated by pulmonary surfactant and should not be used for CA pneumonia due to CA MRSA [ 45 ].”
BackgroundEmerging Options for Treatment of Invasive, Multidrug‐Resistant Staphylococcus aureus Infections
Drew, R. H. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.227 · Cited by 123
“Subsequent studies have revealed the role of pulmonary surfactant in inhibiting the antibacterial activity of daptomycin.(189) Thus, pulmonary infections that are acquired hematogenously may be of less concern than those acquired through inhalation.”
BackgroundRehm, S. J., Boucher, H. W., Levine, D. P., Campion, M., Eisenstein, B. I., Vigliani, G. A., Corey, G. R., & Abrutyn, E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn372 · Cited by 119
“aureus infections of the lung.(21) Because stringent criteria were used to define outcomes, the overall success rates in both treatment arms were low.”
BackgroundDaptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Vilhena, C., & Bettencourt, A. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557511209030202 · Cited by 113
“Daptomycin cannot be used to treat pneumonia and respiratory disease, due its inactivation in the presence of pulmonary surfactant [3, 73].”
BackgroundTherapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections
Cairns, K. A., Udy, A. A., Peel, T. N., Abbott, I. J., Dooley, M. J., & Peleg, A. Y. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-22 · Cited by 111
“Daptomycin has relatively good penetration into most body sites; however, it is inhibited by pulmonary surfactants and therefore should not be used for primary infections of the lung (104).”
BackgroundRybak, M. J. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01342.x · Cited by 110
“However, the primary endpoint was not met, possibly as a consequence of the significant reduction in activity of daptomycin in the presence of pulmonary surfactant [52].”
BackgroundNguyen, K. T., He, X., Alexander, D. C., Li, C., Gu, J.-Q., Mascio, C. T. M., Praagh, A. D. G. V., Mortin, L., Chu, M., Silverman, J. A., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01307-09 · Cited by 109
“cin in surfactant in the lung alveolar space (40).”
BackgroundSelf-citationBush, K. (2012) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.31.1.2096 · Cited by 104
Satlin, M. J., & Walsh, T. J. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12762 · Cited by 104
“Daptomycin is not an effective therapy for pneumonia because it is inactivated by alveolar surfactants.(118) Furthermore, daptomycin resistance in VRE has been increasingly reported,(119) particularly in patients with hematologic malignancies.”
BackgroundInfectious Diseases Society of America (IDSA) (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis688 · Cited by 107
“underscores the need to establish that an antibacterial agent not only penetrates into the target tissues but also retains antibacterial activity in those tissues [56].”
BackgroundSader, H. S., & Jones, R. N. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.06.016 · Cited by 100
“However, daptomycin is not indicated for treatment of pneumonia, because of its inhibition by pulmonary surfactants [15].”
BackgroundTong, S. Y. C., Chen, L. F., & Fowler, V. G. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0300-x · Cited by 122
“Importantly, daptomycin should not be used for the treatment of staphylococcal pneumonia as pulmonary surfactant inhibits the action of daptomycin [150] and creatine kinase levels should be monitored weekly during therapy.”
BackgroundMartinez, M. N., & Silley, P. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-10324-7_10 · Cited by 101
Reck, F., Alm, R. A., Brassil, P. J., Newman, J. V., Ciaccio, P. J., McNulty, J. M., Barthlow, H. G., Goteti, K., Breen, J. N., Comita-Prevoir, J., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300690s · Cited by 96
Current and future treatment options for community-associated MRSA infection
Khan, A. H., Wilson, B., & Gould, I. M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1442826 · Cited by 99
“non-hematogenous MRSA pneumonia due to its activity being inhibited by pulmonary surfactant [60].”
BackgroundMethicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment
Parsons, J. B., Mourad, A., Conlon, B. P., Kielian, T., & Fowler, V. G. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01226-2 · Cited by 104
“For example, daptomycin is ineffective against S. aureus pneumonia because it binds to lung surfactant, which inhibits its interaction with bacterial cell membranes 129”
Comparative and Veterinary Pharmacology
Cunningham, F. M., Elliott, J., & Lees, P. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-10324-7 · Cited by 98
Casey, A. L., Lambert, P. A., & Elliott, T. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)72175-1 · Cited by 133
Daptomycin Therapy for Invasive Gram-Positive Bacterial Infections in Children
Ardura, M. I., Mejías, A., Katz, K. S., Revell, P., McCracken, G. H., & Sánchez, P. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31814523f8 · Cited by 87
“Daptomycin is not indicated for treatment of pneumonia because of poor penetration into lung epithelial lining fluid and its inactivation by pulmonary surfactant.(20) Although 8 of our patients had pneumonia, they continued to receive therapy with vancomycin.”
BackgroundWelte, T., & Pletz, M. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.045 · Cited by 94
“has demonstrated good activity against MRSA it is inactivated by pulmonary surfactant in animal models [77] and did not achieve non-inferiority to ceftriaxone in clinical trials of pneumonia [78].”
BackgroundEnoch, D., Bygott, J. M., Daly, M., & Karas, J. A. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.05.180 · Cited by 85
Kim, P. W., Sorbello, A. F., Wassel, R. T., Pham, T. M., Tonning, J. M., & Nambiar, S. (2012) · Drug Safety · doi:10.2165/11597460-000000000-00000 · Cited by 84
Bal, A. M., David, M. Z., Garau, J., Gottlieb, T., Mazzei, T., Scaglione, F., Tattevin, P., & Gould, I. M. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.05.019 · Cited by 83
Scheetz, M. H., Wunderink, R. G., Postelnick, M. J., & Noskin, G. A. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.4.539 · Cited by 83
Mechanism of Action and Limited Cross-Resistance of New Lipopeptide MX-2401
Rubinchik, E., Schneider, T., Elliott, M. R., Scott, W. R. P., Pan, J., Anklin, C. G., Yang, H., Dugourd, D., Müller, A., Gries, K., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00170-11 · Cited by 80
“In contrast to the lipopeptide daptomycin, the activity of MX-2401 was not inhibited in the presence of lung surfactant, and the drug shows promising activity in a bronchialalveolar pneumonia model in which daptomycin was not active (13, 35).”
BackgroundInfluentialManagement of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy
Bassetti, M., Taramasso, L., Giacobbe, D. R., & Pelosi, P. P. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.36 · Cited by 90
Daptomycin-induced eosinophilic pneumonia - a systematic review
Uppal, P., LaPlante, K. L., Gaitanis, M. M., Jankowich, M. D., & Ward, K. E. (2016) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-016-0158-8 · Cited by 79
“pulmonary endothelial cells, airway smooth muscle cells, and alveolar epithelial cells leads to further accumulation of eosinophils in the lungs [5].”
Gotfried, M. H., Shaw, J., Benton, B. M., Krause, K. M., Goldberg, M. R., Kitt, M. M., & Barriere, S. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00875-07 · Cited by 79
“The penetration of lung tissues by antimicrobial agents does not always predict the eradication of susceptible pathogens, as the agents’ pharmacodynamics can be adversely affected by the unique physiology of the respiratory system (24, 31).”
BackgroundHair, P. I., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767100-00008 · Cited by 90
Zasowski, E. J., Trinh, T. D., Claeys, K. C., Casapao, A. M., Sabagha, N., Lagnf, A. M., Klinker, K. P., Davis, S. L., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02015-16 · Cited by 82
“Interactions with pulmonary surfactant render daptomycin ineffective for BSI secondary to a respiratory source (12).”
BackgroundMethicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?
Kollef, M. H., & Micek, S. T. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000216627.13445.e2 · Cited by 79
Bionda, N., Pitteloud, J., & Čudić, P. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.86 · Cited by 77
What's new on the antimicrobial horizon?
Song, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70004-4 · Cited by 77
Ancajas, C. M. F., Oyedele, A. S., Butt, C. M., & Walker, A. S. (2024) · Natural Product Reports · doi:10.1039/d4np00009a · Cited by 82
Solid-Phase Total Synthesis of Daptomycin and Analogs
Lohani, C. R., Taylor, R., Palmer, M., & Taylor, S. D. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b00043 · Cited by 80
Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections
Douglas, E. J. A., Wulandari, S. W., Lovell, S., & Laabei, M. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14268 · Cited by 81
Alexander, D. C., Rock, J. L., He, X., Brian, P., Miao, V., & Baltz, R. H. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.01248-10 · Cited by 70
“In vitro studies have shown that daptomycin becomes sequestered in bovine pulmonary surfactant, most likely in the lipid component, and has decreased antibacterial potency against Grampositive pathogens (46); this may be a significant factor contributing to the poor clinical efficacy in CAP.”
BackgroundFalagas, M. E., Giannopoulou, K., Ntziora, F., & Papagelopoulos, P. J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.012 · Cited by 70
Therapeutic applications of lysostaphin against Staphylococcus aureus
Jayakumar, J. S., Kumar, V. A., Biswas, L., & Biswas, R. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14985 · Cited by 74
“Daptomycin gets inactivated by the lung surfactant, so it cannot be used to treat pulmonary infections (Silverman et al. 2005).”
BackgroundWang, S., Wang, Q., Zeng, X., Ye, Q., Huang, S., Yu, H., Yang, T., & Qiao, S. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02592 · Cited by 67
Managing community-acquired pneumonia: A European perspective
Lode, H. M. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.04.008 · Cited by 74
“The lipopeptide, daptomycin failed to meet statistical noninferiority criteria in an in vitro modeling trial.(56) It was shown to interact with pulmonary surfactant, resulting in inhibition of antibacterial activity; it was efficacious to Staphylococcus aureus heamatogenous pneumonia, but demonstrated no activity agai…”
BackgroundMethicillin-resistant Staphylococcus aureus in HIV-infected patients
Hidrón, A., Moanna, A., Kempker, R. R., & Rimland, D. (2010) · Infection and Drug Resistance · doi:10.2147/idr.s7641 · Cited by 73
“Daptomycin should not be used for the treatment of MRSA pneumonia because the drug is inactivated by pulmonary surfactant causing clinical failures.(148) Of note, daptomycin use has been associated with elevated creatine kinase, myopathy, and even rhabdomyolysis in some cases.”
Pathogens Resistant to Antibacterial Agents
Chen, L. F., Chopra, T., & Kaye, K. S. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.002 · Cited by 76
“Daptomycin is inactivated by alveolar surfactants, and should not be used for pulmonary infections.(61)”
BackgroundAntimicrobial-resistantStreptococcus pneumoniae: trends and management
Jacobs, M. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.619 · Cited by 62
Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions
Rowe, S. E., Beam, J. E., & Conlon, B. P. (2021) · Infection and Immunity · doi:10.1128/iai.00694-20 · Cited by 64
“ineffective in the treatment of pneumonia or cystic fibrosis-associated infection (73).”
Background
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.